Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  draadje Malaria

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

draadje Malaria

439 Posts
Pagina: «« 1 ... 16 17 18 19 20 ... 22 »» | Laatste | Omlaag ↓
  1. flosz 29 juli 2009 10:34
    quote:

    pardon schreef:

    BAGAMOYO, TANZANIA, May 27, 2009 — The Phase 3 trial of the most clinically advanced malaria vaccine candidate began May 26 with inoculations administered at the Bagamoyo Research and Training Centre of the Ifakara Health Institute (IHI) in Tanzania.
    Zie o.a. pag. 32 en 33.
    www.iex.nl/forum/topic.asp?forum=228&...
    www.iex.nl/forum/topic.asp?forum=228&...
    www.malariavaccine.org/files/05272009...
    En www.ifpma.org/documents/NR12400/Statu... pagina 3
    Crucell/ MVI/ AdVac®-based malaria vaccine/ Preclinical
    Crucell/NIAID/ AdVac®-based malaria vaccine/ Clinical
    GlaxoSmithKline/ MVI/ RTS,S/AS01E vaccine/ Phase III
  2. flosz 29 juli 2009 10:49
    Soms plakken de stukjes extra lekker....

    Crucell wins funding for malaria vaccine development
    Wed Jul 29, 2009 6:45am
    * Crucell, Malaria Vaccine Initiative to conduct studies
    * Funding provided by U.S-based agency USAID
    AMSTERDAM, July 29 (Reuters) - Dutch biotechnology firm Crucell (CRCL.AS) (CRXL.O) said on Wednesday it had gained funding to accelerate the development of a malaria vaccine as it entered into a collaboration with two U.S.-based organisations.
    Crucell said it has entered into the collaboration with the PATH Malaria Vaccine Initiative (MVI) and the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP).
    Via funding from the MVDP, both Crucell and MVI will conduct studies to determine the effectiveness of Crucell's vaccine against the malaria parasite. Crucell did not disclose any financial details.
    "This agreement is a strong validation of Crucell's malaria vaccine approach," Crucell's chief scientific officer, Jaap Goudsmit, said in a statement.
    Crucell is developing a malaria vaccine based on the company's AdVac technology, which allows for the insertion of genetic material from the virus into a 'vehicle' that delivers a vaccine, and the PER.C6 gene technology which uses human cells as a platform to produce drugs.
    The company is already involved in Phase I trials of its malaria vaccine with the National Institutes of Health (NIH) in the United States.
    www.reuters.com/article/marketsNews/i...
  3. forum rang 4 aossa 29 juli 2009 14:29
    www.genvec.com/go.cfm?do=Press.List

    GenVec Receives Grant for Malaria Vaccine Program
    07/29/09

    GenVec Expands Contract Supporting Malaria Vaccine Program
    07/27/09

    GENVEC RECEIVES GRANT FOR MALARIA VACCINE PROGRAM
    GAITHERSBURG, MD – July 29, 2009 – GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the company’s malaria vaccine program.
    “We appreciate the support this grant offers GenVec. This funding supports the advancement of GenVec technology by moving GenVec into the antigen discovery phase of vaccine development,” said Dr. Joseph Bruder, head of GenVec’s malaria program.
    This grant, valued at approximately $600,000 over two years, will be used to identify new immunogenic antigens for malaria vaccine development. Using the funding from this grant, GenVec will be collaborating with the U.S. Naval Medical Research Center (NMRC) to apply its adenovector technology to the development of malaria vaccine candidates.
    About GenVec
    GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec’s lead product, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company’s various filings with the Securities and Exchange Commission.

    GAITHERSBURG, Md., July 27 /PRNewswire-FirstCall/ -- Today GenVec, Inc. (Nasdaq: GNVC - News) announced the expansion of an existing contract with the PATH Malaria Vaccine Initiative (MVI) to support the development of vaccines to fight malaria through MVI and USAID funding. This contract, valued at approximately $2 million, will continue a collaboration that began in 2004 and will initially support preclinical feasibility studies of novel adenovirus-based vaccines. Based on the results of the feasibility studies, GenVec, MVI, and USAID will contemplate preclinical and clinical development of these vaccines.

    "We appreciate the continued support from MVI and USAID and we look forward to advancing GenVec's vaccine technology through this collaboration," stated Dr. Joseph Bruder, head of GenVec's malaria program.
  4. forum rang 4 aossa 29 juli 2009 14:40
    About the malaria vaccine roadmap

    Global strategy aims to accelerate vaccine development

    The world’s leading international health organizations have developed a global strategy for accelerating the development and licensing of a highly effective malaria vaccine.

    The plan is known as the Malaria Vaccine Technology Roadmap. It calls for the malaria vaccine community—scientists, funding organizations, policy experts, and national and global decision-makers—to develop an effective vaccine that prevents severe disease and death caused by Plasmodium falciparum, the most deadly form of the malaria parasite. The roadmap outlines a path toward:

    * Developing and licensing a first-generation vaccine by 2015 with 50 percent protective efficacy against severe disease and death that would last longer than one year.
    * Developing a malaria vaccine by 2025 that would have a protective efficacy of more than 80 percent against clinical disease and that would provide protection for longer than four years.

    Click to download a full copy of the Malaria Vaccine Technology Roadmap (462 KB PDF) or download the executive summary (243 KB PDF).

    Learn more about the Malaria Vaccine Technology Roadmap:
    www.malariavaccineroadmap.net.

    www.malariavaccine.org/malvac-roadmap...
  5. [verwijderd] 30 juli 2009 00:18
    wo 29 jul 2009, 23:00

    'Volledige bescherming tegen malaria is mogelijk'

    NIJMEGEN - Volledige bescherming tegen malaria is mogelijk. Dat stellen wetenschappers van het Universitair Medisch Centrum St Radboud (UMC) in Nijmegen na onderzoek met hulp van proefpersonen die zich vrijwillig aan malaria lieten blootstellen.

    De vrijwilligers werden besmet met malaria, terwijl zij het antimalariamiddel chloroquine kregen. De onderzoekers constateerden een goede afweerreactie bij de proefpersonen, die geen ziekteverschijnselen vertoonden. Enkele maanden later namen de wetenschappers nogmaals de proef op de som. De vrijwilligers werden opnieuw blootgesteld aan malariaparasieten. Ook nu werden zij niet ziek door de opgebouwde afweerreactie. Volgens de onderzoekers is een groep afweercellen, de zogeheten multifunctionele T-cellen, belangrijk voor de beschermende afweerreactie.

    De studie bewijst dat het mogelijk is om op efficiënte wijze volledige bescherming tegen malaria op te bouwen, aldus de wetenschappers, die er een „hoopvol uitgangspunt voor een toekomstig effectief malariavaccin” in zien. De onderzoeksresultaten staan in medisch-wetenschappelijk tijdschrift The New England Journal of Medicine.

    Malaria behoort tot de ernstigste infectieziekten in de wereld. Jaarlijks sterven meer dan een miljoen mensen aan de gevolgen van de ziekte. Afrika telt de meeste slachtoffers. Vooral jonge kinderen zijn slachtoffer door het ontbreken van een goede afweerreactie.

    www.telegraaf.nl/binnenland/4502278/_...
  6. flosz 30 juli 2009 01:33
    clinicaltrials.gov/show/NCT00442377

    Volume 361:468-477 July 30, 2009
    Number 5
    Protection against a Malaria Challenge by Sporozoite Inoculation
    Meta Roestenberg, M.D., Matthew McCall, M.D., Joost Hopman, M.D., Jorien Wiersma, Adrian J.F. Luty, Ph.D., Geert Jan van Gemert, B.Sc., Marga van de Vegte-Bolmer, B.Sc., Ben van Schaijk, M.Sc., Karina Teelen, Theo Arens, Lopke Spaarman, B.Sc., Quirijn de Mast, M.D., Will Roeffen, Ph.D., Georges Snounou, Ph.D., Laurent Rénia, Ph.D., Andre van der Ven, M.D., Cornelus C. Hermsen, Ph.D., and Robert Sauerwein, M.D.

    Background
    An effective vaccine for malaria is urgently needed. Naturally acquired immunity to malaria develops slowly, and induction of protection in humans can be achieved artificially by the inoculation of radiation-attenuated sporozoites by means of more than 1000 infective mosquito bites.
    Methods We exposed 15 healthy volunteers — with 10 assigned to a vaccine group and 5 assigned to a control group — to bites of mosquitoes once a month for 3 months while they were receiving a prophylactic regimen of chloroquine. The vaccine group was exposed to mosquitoes that were infected with Plasmodium falciparum, and the control group was exposed to mosquitoes that were not infected with the malaria parasite. One month after the discontinuation of chloroquine, protection was assessed by homologous challenge with five mosquitoes infected with P. falciparum. We assessed humoral and cellular responses before vaccination and before the challenge to investigate correlates of protection.
    Results All 10 subjects in the vaccine group were protected against a malaria challenge with the infected mosquitoes. In contrast, patent parasitemia (i.e., parasites found in the blood on microscopical examination) developed in all five control subjects. Adverse events were mainly reported by vaccinees after the first immunization and by control subjects after the challenge; no serious adverse events occurred. In this model, we identified the induction of parasite-specific pluripotent effector memory T cells producing interferon- , tumor necrosis factor , and interleukin-2 as a promising immunologic marker of protection.
    Conclusions Protection against a homologous malaria challenge can be induced by the inoculation of intact sporozoites.

    Volledig art.: content.nejm.org/cgi/content/full/361...

    Van pagina 31.
    Following resistance of malaria to drugs like chloroquine, the Government and the World Health Organisation (WHO) recommended a new class of anti-malarial medicines called Artemisinin Combination Therapies (ACTs).
    www.iex.nl/forum/topic.asp?forum=228&...

    En pagina 7 (2006).
    Malaria morbidity and mortality rates are rising in developing countries, largely due to the emergence of drug resistant parasites rendering traditional antimalarial drugs, such as chloroquine and sulfadoxine-pyrimethamine (SP) ineffective.
    www.iex.nl/forum/topic.asp?forum=228&...

    Artemisinin Resistance in Plasmodium falciparum Malaria
    content.nejm.org/cgi/content/full/361...
  7. [verwijderd] 30 juli 2009 08:14
    Radboud: bescherming tegen malaria mogelijk
    door Paul Bolwerk. donderdag 30 juli 2009 | 07:00 | Laatst bijgewerkt op: donderdag 30 juli 2009 | 07:55


    Volgens het internationale Rode Kruis is de wereldwijde uitbanning van Malaria echter niet haalbaar als muskietennetten het belangrijkste middel in de bestrijding van de ziekte blijft. ANP

    NIJMEGEN - Volledige bescherming tegen malaria is mogelijk. Dat stellen wetenschappers van het Universitair Medisch Centrum St Radboud (UMC) in Nijmegen na onderzoek op proefpersonen die zich vrijwillig aan besmette malariamuggen hebben laten blootstellen.

    Het onderzoek is verricht in samenwerking met het Singapore Immunologisch Netwerk en het National Institute of Health and Medical Research in Parijs.

    Ze melden de onderzoeksresultaten vandaag in het gezaghebbende medisch-wetenschappelijke tijdschrift The New England Journal of Medicine.

    Volgens de onderzoekers is een groep afweercellen, de zogeheten multifunctionele T-cellen, belangrijk voor de beschermende afweerreactie. " Dat volledige bescherming tegen malaria mogelijk is, is een hoopvol uitgangspunt voor een toekomstig effectief malariavaccin", zegt de Nijmeegse onderzoeksgroep.

    Al tientallen jaren wordt gezocht naar een vaccin om de mens volledig te beschermen tegen malaria. Malaria behoort tot de ernstigste infectieziekten in de wereld. Jaarlijks sterven vooral in Afrika meer dan een miljoen mensen aan de gevolgen van malaria.

    Dirk

    www.gelderlander.nl/voorpagina/nijmeg...
  8. flosz 30 juli 2009 15:34
    Published online 29 July 2009 | Nature | doi:10.1038/news.2009.750

    Malaria becoming more drug resistant
    Artemisinin-based medicines fail a growing number of patients in Cambodia.
    Katharine Sanderson

    Malaria parasites in Cambodia are becoming increasingly resistant to the drug hailed as the world's best chance to eradicate the disease.
    Artemisinin-based drugs are currently the best weapon against malaria, a disease which kills around a million people every year and is spread by mosquitoes carrying malaria parasites such as Plasmodium falciparum. These parasites have already developed resistance to drugs such as chloroquine and sulfadoxine-pyrimethamine, once the front line against the disease, so hopes have been pinned on artemisinin-combination therapies (ACTs).
    The parasites have become far less easy to treat with ACTs, however, in the Cambodian city of Pailin, close to the country's western border with Thailand. The finding was made by researchers from the Wellcome Trust–Mahidol University Oxford Tropical Medicine Research Programme, based in Bangkok, Thailand.
    In particular, the parasites are becoming more resistant to a combined therapy of artesunate, derived from artemisinin, and mefloquine, a quinine analogue. This combination is used to treat malaria worldwide.
    Rumours about artemisinin resistance in Cambodia have been circulating for a number of years, and a relatively small study by Harald Noedl at the Medical University of Vienna and his colleagues, published late last year, suggested that resistance was emerging1.
    Cambodia and Thailand
    The latest study involved 40 patients infected with P. falciparum in Pailin, and another 40 in Wang Pha, in northwest Thailand2. Half of each group were given just artesunate, and the other half the dual artesunate–mefloquine therapy.
    The Cambodian group took almost twice as long to clear the parasite from their body as the Thai group: 84 hours compared with 48 hours. Usually artemisinin drugs clear the parasite within three days, says Nick Day, director of the Mahidol Oxford research unit in Bangkok and co-author of the study, published in the New England Journal of Medicine.
    Infection broke out again for six of the twenty patients taking just artesunate in Cambodia, compared with two patients in Thailand. With the combined therapy, it recurred in only one of the twenty cases in each group.
    The World Health Organization recommends that artemisinin-based drugs be given only in combination, to delay the onset of resistance. But Day explains that the single-dose groups were crucial in their controlled study to show that there was growing resistance to artesunate, and not to mefloquine alone.
    The emergence of artemisinin-resistant malaria in Cambodia is especially worrying, because previous drug-resistant strains of malaria have sprung from there. "This is a wake-up call," says Day. "We have got reduced susceptibility to the drugs in an area where we've seen resistance emerge before." Given time, the parasite will only become more resistant to the drugs, he adds.
    Accelerate and eradicate
    The research offers a clear warning that efforts to eradicate malaria should be accelerated, says Sanjeev Krishna from St George's University of London, who studies the biochemical origins of artemisinin resistance. He says that he expected resistance to occur eventually — but not as soon as this. "I thought we would have had longer," he says. More intensive drug-development programmes are needed, he adds, to find new drugs based on artemisinin, as well as alternatives.
    An eradication programme combining continued treatment and use of mosquito nets is under way in this area of Cambodia, Day says. "It's going to need considerable political willpower, scientific research and financial resources to achieve," he cautions. But without it, there is a danger that the resistant parasite could reach the world's malaria heartland — Africa. "That," says Day, "would be a major disaster."
    www.nature.com/news/2009/090729/full/...
  10. yinx 30 juli 2009 16:37
    quote:

    oudje schreef:

    Radboud:
    Welke onderneming gaat als de bok op de haverkist zitten? Ofwel: wie biedt het meest??
    www.sanaria.com/index.php?s=42

    www.nu.nl/wetenschap/1393865/nederlan...

    Nederlanders werken aan vaccin tegen malaria
    Uitgegeven: 16 januari 2008 11:58
    Laatst gewijzigd: 16 januari 2008 12:14

    LEIDEN - De universitaire medische centra in Nijmegen en Leiden zijn begonnen met onderzoek naar een vaccin tegen malaria. Zij doen dit in samenwerking met het Amerikaans biotechnologiebedrijf Sanaria.

    Dit heeft Top Instituut Pharma, waarin kennisinstellingen en farmaceuten samenwerken, woensdag bekendgemaakt.

    Voor het project, dat vier jaar zal duren, is 16 miljoen euro beschikbaar. Ondanks tientallen jaren onderzoek, is er momenteel geen commercieel vaccin tegen malaria beschikbaar.

  11. flosz 30 juli 2009 21:15
    Mosquitoes against malaria? - July 30, 2009
    Two malaria papers out this week in the New England Journal of Medicine have seen some press coverage. Undoubtedly the more concerning discusses the parasite’s increasing resistance to artemisinin-based drugs in Cambodia – see Nature’s news story.
    The other, as Carlos Campbell of the PATH malaria vaccine initiative writes in an accompanying editorial, “reminds us that the whole malaria parasite is the most potent immunizing antigen identified to date”. In what AP describe as a “daring experiment” with “astounding” results, researchers found that ten people subjected to mosquito bites three times over three months whilst taking the drug chloroquine gained apparent immunity against malarial mosquito bites a month later.
    It’s hard to see, however, that this finding adds much new to the vaccine-hunter’s arsenal.
    It’s been known since the 1960s that sporozoites, cells that travel from the insect’s salivary gland to the bitten human’s liver can help provide immunity (which is why the first bout of malaria is usually the worst). This study has confirmed that. The difficulty is using this tactic to actually immunize patients – producing whole sporozoites for a real vaccine requires the breeding of many live mosquitoes and human blood to test on. As Campbell adds in his editorial, the carefully timed and controlled mosquito-inoculation approach, so far removed from the real world, “cannot be the basis for a human malaria vaccine”.
    Right now, though, production of irradiated and weakened sporozoites – garnered from irradiated mosquitoes – is ongoing www.sanaria.com/pdf/AP%20060809.pdf for injection in first-stage (safety) human trials at Maryland-based biotech company Sanaria (an effort that has taken over three decades). Meanwhile, in a PNAS paper tinyurl.com/l5lgvn last week which did not go through a rigorous peer review procedure, a collaboration of researchers reported that human trials would begin in early 2010 for another similar approach: this time weakening the sporozoite by snipping out two genes, rather than irradiating malaria.
    Other malaria vaccine trials are based on using protein fragments, rather than the whole sporozoite to induce immunity. These include Glaxo’s RTS,S www.nature.com/news/2008/080227/full/... phase III trials which began www.nature.com/news/2009/090527/full/... a few months ago; while Dutch pharmaceutical company Crucell recently announced www.reuters.com/article/rbssHealthcar... a collaboration with the PATH malaria vaccine initiative, to use adenoviruses to deliver a malaria antigen to the immune system. (The MVI has a full list of malaria vaccines in development). www.malariavaccine.org/rd-portfolio.php
    blogs.nature.com/news/thegreatbeyond/...
  12. [verwijderd] 31 juli 2009 11:55
    Zo te lezen wordt de aanpak van Crucell toch gezien als de meest kansrijke.

    Dat er geen bedrag wordt genoemd heet denk ik te maken met de gezamenlijke redactie van het persbericht.

    Verder kan het bedrag van bepaalde zaken afhangen zodat dit nog niet gecommuniceerd kon worden.
    Komt vast op 11 augustus aan de orde.
  13. flosz 4 augustus 2009 10:02
    Original source of malaria reported
    Deadly parasite jumped to humans from chimpanzees, perhaps through one mosquito
    Researchers have identified what they believe is the original source of malignant malaria: a parasite found in chimpanzees in equatorial Africa.
    UC Irvine biologist Francisco Ayala and colleagues think the deadly parasite was transmitted to humans from chimpanzees perhaps as recently as 5,000 years ago - and possibly through a single mosquito, genetic analyses indicate. Previously, malaria's origin had been unclear.
    This discovery could aid the development of a vaccine for malaria, which sickens about 500 million people and kills about 1.5 million each year. It also furthers understanding of how infectious diseases such as HIV, SARS, and avian and swine flu can be transmitted to humans from animals.
    "When malaria transferred to humans, it became very severe very quickly," said Ayala, co-author of the study that reports these findings. "The disease in humans has become resistant to many drugs. It's my hope that our discovery will bring us closer to making a vaccine."
    The study appears online the week of Aug. 3 in the Proceedings of the National Academy of Sciences.
    Human malignant malaria is caused by a parasite called Plasmodium falciparum, which is responsible for 85 percent of all infections and nearly all malaria deaths. Chimpanzees were known to carry a closely related parasite called Plasmodium reichenowi, but most scientists assumed the two had existed separately in humans and chimpanzees for the last 5 million years.
    Scientists in the current study examined several new strains of the parasite found in blood taken from wild and wild-born chimpanzees in Cameroon and Ivory Coast sanctuaries during routine health exams.
    A gene analysis linked one chimpanzee strain to all worldwide strains of the human malaria parasite. This connection suggests that one mosquito may have transferred malaria to humans. Because there is little genetic variance among strains of the human parasite, scientists believe the transmission occurred in the recent past - maybe 5,000 to 2 million years ago - though an exact time could not be determined.
    The results support an earlier hypothesis by Dr. Ajit Varki of UC San Diego and colleagues that genetic mutations made humans first resistant to sickness from the chimpanzee parasite, then extremely susceptible to illness from the human form.
    They also corroborate an earlier finding by Ayala and former UCI graduate student Stephen Rich that malignant malaria started spreading throughout the tropics and world about 5,000 years ago, when agriculture began in Africa. Rich, now a professor at the University of Massachusetts Amherst, is the lead author of the current PNAS study.
    In addition to Ayala and Rich, Nathan Wolfe of Stanford University worked on the study, along with collaborators from the Robert Koch Institute and the Max Planck Institute for Evolutionary Anthropology in Germany; the Global Viral Forecasting Initiative in San Francisco; the Biotechnology Centre in Cameroon; the U.S. Department of Agriculture; and the Ebola Tai Forest Project in the Ivory Coast.
    The study was funded by the National Institutes of Health, with additional support from the Cummings School of Veterinary Medicine at Tufts University and the National Geographic Society Committee for Research & Exploration.
    — Jennifer Fitzenberger, University Communications
    www.uci.edu/uci/features/feature_mala...
  14. flosz 15 september 2009 08:45
    We're very keen to develop a vaccine against malaria; we did three years ago, worked together with GlaxoSmithKline on the RTSS. The US Army has done several studies to combine the two vaccine components, unfortunately three years ago we got a bit -- ended up into a kind of a -- I wouldn't say fight… but a kind of, yes, we couldn't agree on the terms of
    further development with GlaxoSmithKline. At this moment of time, we are again on
    speaking terms and world needs a very good malaria vaccine and the RTSS from Glaxo
    so far did not go beyond an efficacy number of 50%.
    We believe using it has a prime boost in combination with our vaccine will draw the
    efficacy up to 80%.
    ….
    Now very importantly, we're going to pursue new
    partnerships because we feel that the products like malaria and tuberculosis are now in a
    certain stage of development that is wise to seek partnerships for those. But those
    partnerships will be distinctly different than the ones that we closed in the early days of
    our incorporation in 2003 and 2004. We always will seek geographical sales and
    geographical rights in partnerships that we are going to pursue. On top of that I think we
    are prone to report to you, important progress in the clinical development of our pipeline
    at the end of the year and we will continue to see if we can increase the point of base of
    82 to a much higher number, and thereby basically creating and increasing the probability
    of having big growth history that’s coming up to Crucell.

    hugin.info/132631/R/1322779/310208.pdf
  15. [verwijderd] 17 september 2009 16:23
    Nieuwe methode tegen malariabesmetting kinderen
    LONDEN - Een nieuwe methode om het aantal besmettingen met malaria bij baby's in Afrika te verminderen, is succesvol gebleken. Het gaat om het zogeheten Preventive Treatment of malaria in Infants (IPTi) waarbij het medicijn sulphadoxine-pyrimethamine (SP) wordt toegediend.

    Naar de methode is negen jaar onderzoek gedaan door Unicef, de Wereld Gezondheids Organisatie (WHO) en zeventien onderzoeksinstituten. De resultaten zijn donderdag gepubliceerd in het gezaghebbende tijdschrift The Lancet.

    Volgens de onderzoekers is IPTi een „veilige, betaalbare en makkelijke methode die het aantal besmettingen van malaria in Afrika in het eerste levensjaar met 30 procent kan verminderen.”

    Zes klinische tests met IPTi en SP hadden plaats in Mozambique, Gabon, Tanzania en Ghana. Als de methode in meer Afrikaanse landen wordt toegepast kan het zes miljoen besmettingen per jaar voorkomen, aldus de onderzoekers. Kinderen kregen in het eerste levensjaar twee tot drie keer een tablet. Duur is het medicijn niet: tussen de 13 en 23 dollarcent per tablet.

    IPTi is tevens de naam van een consortium dat is gelieerd aan de universiteit van Barcelona. Het wordt financieel ondersteund door Bill en Melinda Gates

    www.telegraaf.nl/buitenland/4859551/_...

    DRW
  16. [verwijderd] 21 september 2009 22:40
    Schimmel tegen resistente malariamug WAGENINGEN - Schimmels zijn effectief tegen malariamuggen, die resistent zijn tegen chemische bestrijdingsmiddelen. Dat hebben onderzoekers van onder meer de Wageningen Universiteit vastgesteld na onderzoek in Zuid-Afrika.

    Sporen van de schimmel Beauveria bassiana kunnen muggen na infectie binnen enkele dagen doden. De infectie vermindert bovendien de eetlust van de mug en belemmert de ontwikkeling van malariaparasieten.

    Uit het onderzoek in Zuid-Afrika blijkt dat ook resistente muggen vatbaar zijn voor de schimmel. De resistentie van die muggen tegen bestrijdingsmiddelen neemt bovendien af na infectie. De onderzoekers denken dat de gifstoffen in de schimmels het resistentiemechanisme van de mug ondermijnen.

    Malariamuggen zijn steeds beter bestand tegen gangbare verdelgingsmiddelen als DDT. Buiten die middelen zijn er weinig opties voor muggenbestrijding binnenshuis. Het onderzoek laat echter de potentie van schimmels zien als effectief biologisch bestrijdingsmiddel tegen malariamuggen, aldus de wetenschappers.

    Jaarlijks eist malaria meer dan een miljoen mensenlevens. Vooral Afrikaanse kinderen jonger dan vijf jaar en zwangere vrouwen zijn slachtoffer. Ruim drie miljard mensen wonen in gebieden waar malaria voorkomt.

    www.telegraaf.nl/binnenland/4889897/_...
  17. flosz 8 oktober 2009 10:55
    Plos art. GSK.
    www.plosone.org/article/fetchObjectAt...

    Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.

    CONCLUSIONS: Both candidate malaria vaccines were well tolerated. Anti-circumsporozoite responses were greater with RTS,S/AS01(E) than RTS,S/AS02(D) and when 3 rather than 2 doses were given. This study supports the selection of RTS,S/AS01(E) and a 3 dose schedule for further development in children and infants.

    www.clinicaltrials.gov/ct2/show/NCT00...
  18. flosz 4 november 2009 09:39
    World’s largest malaria vaccine trial now underway in seven African countries
    Pivotal testing of RTS,S is on track for target enrollment of 16,000 children
    NAIROBI, KENYA November 3, 2009
    A pivotal efficacy trial of RTS,S, the world’s most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced Tuesday at the 5th Multilateral Initiative on Malaria Pan-African Malaria Conference.
    Developing a vaccine against malaria, a scientific challenge for decades, is critical to defeating the disease. A vaccine would complement existing interventions, such as bed nets and effective drug therapies. GlaxoSmithKline Biologicals’ (GSK Bio) RTS,S is the first malaria vaccine candidate to demonstrate significant efficacy during early development to warrant Phase III testing. It is the leading vaccine candidate in the global effort by the PATH Malaria Vaccine Initiative (MVI) to develop a malaria vaccine.
    “A malaria vaccine could help save countless lives and redefine the future for Africa’s children,” said Dr. Patricia Njuguna, RTS,S principal investigator (KEMRI-Wellcome Trust, Kilifi, Kenya) and chair of the Clinical Trials Partnership Committee, a collaboration of African research institutions, MVI, and GSK Bio that is leading the clinical development of RTS,S. “Communities all across Africa are dedicated to this future and are participating to ensure that we develop a vaccine with an acceptable safety and efficacy profile.”
    RTS,S is the first vaccine designed primarily for use in Africa, where malaria kills more than 800,000 people every year, the majority of them children under the age of five. By conducting the trial in seven different countries across Sub-Saharan Africa, researchers will be able to evaluate the vaccine candidate’s efficacy in a variety of settings, with diverse patterns of malaria transmission. For example, some trial sites are located in areas where there is a year-round threat of malaria, while others experience only seasonal transmission.
    All of the research centers were chosen for their track record of world-class clinical research, strong community relations and commitment to meeting the highest international ethical, medical, clinical and regulatory standards.
    “This is a tremendous moment in the fight against malaria and the culmination of more than two decades of research, including 10 years of clinical trials in Africa,” said Dr. Joe Cohen, co-inventor of RTS,S and Vice President of R&D, Vaccines for Emerging Diseases and HIV, at GSK Biologicals. “The Phase III trial is a huge undertaking that depends on effective coordination between researchers, regulators, families and communities. Everyone involved has invested significant energy and resources to pave the way for what could become the world’s first malaria vaccine.”
    www.gsk.com/media/pressreleases/2009/...
439 Posts
Pagina: «« 1 ... 16 17 18 19 20 ... 22 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 915,56 +0,55%
EUR/USD 1,0847 +0,21%
FTSE 100 8.372,12 +0,02%
Germany40^ 18.723,20 +0,23%
Gold spot 2.365,98 -0,52%
NY-Nasdaq Composite 16.801,54 -0,18%

Stijgers

EVS
+2,52%
Ontex
+1,87%
UCB
+1,02%
Colruyt
+1,01%
AZELIS...
+0,86%

Dalers

Ackerm...
-3,17%
Umicore
-2,51%
Elia
-2,00%
IBA
-1,97%
Aedifica
-1,89%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!